Skin Cancer (Nonmelanoma)

A recent survey shows that many consumers are confused about sunscreen labeling claims regarding sun protection factor (SPF), allergenicity and other features.

Cutaneous squamous cell carcinoma (cSCC) patients need close clinical follow-up after being diagnosed with the skin cancer because subsequent cSCC development is likely in the following months and years.

A recent study from the University of Missouri School of Medicine investigates when is the best time to make post-operative phone calls to patients following Mohs micrographic surgeries.

Castle Biosciences announces the launch of DecisionDx-SCC, a prognostic gene expression profile test for patients with high-risk cutaneous squamous cell carcinoma (cSCC).

The International Skin Imaging Collaboration is an academic and industry partnership designed to facilitate the clinical application of digital skin imaging, with an initial focus on melanoma. The group is developing standards for dermatologic imaging and building a public archive of clinical and dermoscopic images for use in developing artificial intelligence diagnostic algorithms.

Findings from a survey of college students examining beliefs about UV exposure and sunscreen use and their associations with skin cancer risk and UV protective behaviors provide some insights for patient counseling.

Findings of initial studies and call for further testing should not be misconstrued to mean ingredients are unsafe.

Treatment for Merkel cell carcinoma has evolved due to the high aggressiveness and metastatic rate of the tumors. Immune checkpoint inhibitor therapy may change prognosis and quality of life.

The biology of nonmelanoma skin cancers and their strong immunogenicity makes these tumors good candidates for novel and emerging immunotherapeutic agents.

The U.S. Food and Drug Administration has approved pembrolizumab for cutaneous squamous cell carcinoma whose disease has shown to not be curable by radiation or surgery.